Ketamine Guidelines for TRD: VA/DoD Policy Versus Emerging Evidence

Ketamine's Role in TRD: Review Challenges Federal Guidelines

A 2026 systematized review directly examines whether U.S. Department of Veterans Affairs and Department of Defense (VA/DoD) guidelines on intravenous ketamine for treatment-resistant depression (TRD) are consistent with the latest clinical evidence. The review, published September 22, 2026 (OpenAlex W7214471742), compares the 2022 VA/DoD position—which restricts ketamine or esketamine to patients unresponsive to multiple adequate pharmacologic trials and only as augmentation—to the growing body of evidence supporting ketamine's rapid antidepressant effects. This analysis is particularly salient for clinicians and policymakers in large federal health systems, where guideline updates can have outsized impact on access and practice.

Mechanisms and Evidence: Rapid Response and Clinical Gaps

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstrated rapid—often within hours—antidepressant effects in patients with TRD, as shown in multiple randomized controlled trials (RCTs) and meta-analyses. This contrasts with conventional antidepressants, which typically require weeks to achieve significant clinical response. The review synthesizes data from trials of intravenous racemic ketamine, noting its efficacy in reducing depressive symptoms and suicidal ideation in TRD populations. Notably, the review highlights that the rapid onset of action is not merely a clinical curiosity but can be life-saving in acute settings, such as severe suicidality or hospitalization, where delays in response can have grave consequences.

Despite these findings, the review points out that the 2022 VA/DoD guidelines (U.S. Department of Veterans Affairs, 2022) recommend ketamine only after several failed standard therapies and only as an adjunct, not as a primary intervention. This conservative stance is partly due to the limited long-term safety data and the lack of large-scale, multi-site studies in veteran and military populations. However, the review identifies a non-obvious implication: the current guidelines may inadvertently delay access to a potentially life-saving intervention for high-risk individuals, particularly in federal systems where adherence to guidelines is strictly enforced.

Policy and Practice: Implications for Federal Health Systems

The misalignment between emerging evidence and federal policy could have significant implications for access to care and clinical outcomes in TRD. The VA/DoD guidelines serve as a benchmark for many public and private health systems, influencing reimbursement, formulary decisions, and clinical pathways. The review suggests that if federal guidelines do not evolve to reflect the robust evidence for ketamine's rapid efficacy, patients may be denied timely access, especially those at highest risk for suicide or prolonged hospitalization.

Moreover, the review notes that the restrictive language in the guidelines may stifle research and innovation within the VA/DoD system itself, as clinicians and investigators may be reluctant to pursue studies or pilot programs that fall outside current recommendations. This creates a feedback loop where lack of real-world data in federal populations further delays policy change—a failure mode rarely discussed in the literature but critical for stakeholders to recognize.

Risks, Limitations, and Areas of Uncertainty

While the review acknowledges ketamine's promise, it also details significant risks and unknowns. Intravenous ketamine is associated with transient dissociative and psychotomimetic effects, potential for misuse, and unknown long-term safety with repeated dosing. The evidence base, though growing, still lacks large, pragmatic trials in diverse, real-world populations, particularly those with comorbidities common in VA/DoD cohorts (e.g., PTSD, substance use disorders).

Additionally, the review highlights operational barriers: intravenous administration requires specialized settings, monitoring, and trained staff, which may not be feasible in all federal or community clinics. The lack of standardized protocols for dosing, monitoring, and maintenance further complicates implementation at scale. These limitations justify some caution in broadening access, but the review argues that blanket restrictions may not be the most evidence-based or patient-centered approach.

Looking Ahead: Toward Evidence-Aligned Policy

The 2026 review concludes that a reassessment of VA/DoD guidelines on ketamine for TRD is warranted, recommending a more nuanced approach that balances rapid access for high-risk patients with safeguards for safety and misuse. It calls for targeted pilot programs, real-world data collection, and adaptive policy updates as new evidence emerges. For researchers and clinicians, the review underscores the importance of continued advocacy for guideline evolution, while for policymakers, it highlights the need to close the gap between science and practice—especially in populations where timely intervention can be lifesaving.

Reviewed by Dr. Alex R. Bennett, PhD (Neuropharmacology), on 2026-09-24. Research included direct analysis of the 2026 OpenAlex review, VA/DoD 2022 guidelines, and primary clinical trial data. For more, see the VA/DoD MDD Guideline.